Surgical Science Sweden Past Earnings Performance
Past criteria checks 3/6
Surgical Science Sweden has been growing earnings at an average annual rate of 66.3%, while the Medical Equipment industry saw earnings growing at 6.3% annually. Revenues have been growing at an average rate of 54% per year. Surgical Science Sweden's return on equity is 5.4%, and it has net margins of 26.5%.
Key information
66.3%
Earnings growth rate
61.7%
EPS growth rate
| Medical Equipment Industry Growth | 6.2% |
| Revenue growth rate | 54.0% |
| Return on equity | 5.4% |
| Net Margin | 26.5% |
| Next Earnings Update | 15 May 2024 |
Recent past performance updates
Recent updates
Earnings Beat: Surgical Science Sweden AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 21
Here's Why Surgical Science Sweden (STO:SUS) Has Caught The Eye Of Investors
Apr 16Surgical Science Sweden AB (publ)'s (STO:SUS) Share Price Is Still Matching Investor Opinion Despite 25% Slump
Mar 17Results: Surgical Science Sweden AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts
Feb 24Is There Now An Opportunity In Surgical Science Sweden AB (publ) (STO:SUS)?
Nov 29Should You Be Adding Surgical Science Sweden (STO:SUS) To Your Watchlist Today?
Oct 07Is Surgical Science Sweden AB (publ) (STO:SUS) Trading At A 39% Discount?
Aug 17With EPS Growth And More, Surgical Science Sweden (STO:SUS) Makes An Interesting Case
Jun 20A Look At The Fair Value Of Surgical Science Sweden AB (publ) (STO:SUS)
May 17Surgical Science Sweden AB (publ) (STO:SUS) Shares Could Be 49% Below Their Intrinsic Value Estimate
Dec 27Is Now The Time To Put Surgical Science Sweden (STO:SUS) On Your Watchlist?
Dec 06Is Now The Time To Look At Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Sep 08We Ran A Stock Scan For Earnings Growth And Surgical Science Sweden (STO:SUS) Passed With Ease
Aug 23Surgical Science Sweden AB (publ) (STO:SUS) Shares Slammed 33% But Getting In Cheap Might Be Difficult Regardless
May 26Here's Why We Think Surgical Science Sweden (STO:SUS) Is Well Worth Watching
Apr 29An Intrinsic Calculation For Surgical Science Sweden AB (publ) (STO:SUS) Suggests It's 44% Undervalued
Feb 20Is It Too Late To Consider Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Jan 11Does Surgical Science Sweden (STO:SUS) Deserve A Spot On Your Watchlist?
Dec 15Calculating The Intrinsic Value Of Surgical Science Sweden AB (publ) (STO:SUS)
Sep 16Is It Too Late To Consider Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Jul 05Calculating The Fair Value Of Surgical Science Sweden AB (publ) (STO:SUS)
Jun 08Is It Too Late To Consider Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Mar 23Calculating The Intrinsic Value Of Surgical Science Sweden AB (publ) (STO:SUS)
Mar 02Is Surgical Science Sweden AB (publ)'s (STO:SUS) Shareholder Ownership Skewed Towards Insiders?
Feb 09
Surgical Science Sweden AB (publ)'s (STO:SUS) Stock Is Going Strong: Have Financials A Role To Play?
Jan 01What Does Surgical Science Sweden AB (publ)'s (STO:SUS) Share Price Indicate?
Dec 14Does Surgical Science Sweden (STO:SUS) Deserve A Spot On Your Watchlist?
Nov 26Revenue & Expenses BreakdownBeta
How Surgical Science Sweden makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 883 | 234 | 240 | 182 |
| 30 Sep 23 | 906 | 253 | 230 | 182 |
| 30 Jun 23 | 901 | 234 | 222 | 185 |
| 31 Mar 23 | 872 | 221 | 215 | 179 |
| 31 Dec 22 | 803 | 188 | 202 | 173 |
| 30 Sep 22 | 750 | 138 | 200 | 159 |
| 30 Jun 22 | 640 | 124 | 176 | 130 |
| 31 Mar 22 | 489 | 101 | 146 | 97 |
| 31 Dec 21 | 367 | 86 | 117 | 66 |
| 30 Sep 21 | 209 | 30 | 76 | 37 |
| 30 Jun 21 | 138 | 21 | 60 | 26 |
| 31 Mar 21 | 122 | 18 | 53 | 20 |
| 31 Dec 20 | 105 | 16 | 50 | 17 |
| 30 Sep 20 | 104 | 14 | 51 | 18 |
| 30 Jun 20 | 112 | 19 | 54 | 19 |
| 31 Mar 20 | 107 | 17 | 52 | 19 |
| 31 Dec 19 | 102 | 13 | 51 | 17 |
| 30 Sep 19 | 88 | 6 | 49 | 15 |
| 30 Jun 19 | 70 | -5 | 43 | 13 |
| 31 Mar 19 | 68 | -5 | 43 | 13 |
| 31 Dec 18 | 66 | -5 | 39 | 14 |
| 30 Sep 18 | 60 | -3 | 38 | 10 |
| 30 Jun 18 | 57 | -6 | 37 | 7 |
| 31 Mar 18 | 56 | -7 | 34 | 4 |
| 31 Dec 17 | 57 | -3 | 31 | 0 |
| 30 Sep 17 | 65 | 4 | 30 | 0 |
| 30 Jun 17 | 60 | 3 | 27 | 0 |
| 31 Mar 17 | 59 | 4 | 27 | 0 |
| 31 Dec 16 | 58 | 3 | 29 | 0 |
| 31 Dec 15 | 52 | 2 | 24 | 0 |
| 31 Dec 14 | 41 | -3 | 21 | 0 |
Quality Earnings: SUS has high quality earnings.
Growing Profit Margin: SUS's current net profit margins (26.5%) are higher than last year (23.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SUS has become profitable over the past 5 years, growing earnings by 66.3% per year.
Accelerating Growth: SUS's earnings growth over the past year (24.5%) is below its 5-year average (66.3% per year).
Earnings vs Industry: SUS earnings growth over the past year (24.5%) did not outperform the Medical Equipment industry 59.4%.
Return on Equity
High ROE: SUS's Return on Equity (5.4%) is considered low.